Hippocampus-targeted BDNF gene therapy to rescue cognitive impairments of Alzheimer's disease in multiple mouse models.
📄 Abstract
Brain-derived neurotrophic factor (BDNF) can protect neurons from apoptosis and maintain normal synaptic structures, indicating a significant potential for Alzheimer's disease (AD) treatment. However, the method of
Confidence:
0.2
· 10 полей извлечено
Идентификация (6 полей)
Target
BDNF
1.00
Alt. target
Brain-derived neurotrophic factor
1.00
Protein family
Neurotrophin
0.90
Functional class
Growth factor
0.90
Subcellular loc.
—
0.00
Isoforms (metab/obesity)
—
0.00
Механизм действия (21 полей)
Mechanism
—
0.00
Mutations (obesity/lean)
—
0.00
Activity (obesity)
—
0.00
Activity temporal
—
0.00
Energy balance
—
0.00
Appetite
—
0.00
Fat metabolism
—
0.00
Lipolysis
—
0.00
Thermogenesis
—
0.00
Muscle metabolism
—
0.00
Inflammation
—
0.00
Glucose metabolism
—
0.00
AA metabolism
—
0.00
Hormonal pathways
—
0.00
Cell death
—
0.00
Adipocyte fibrosis
—
0.00
Upstream (biochem)
—
0.00
Upstream (physiol)
—
0.00
Downstream (biochem)
—
0.00
Downstream (physiol)
—
0.00
PTMs
—
0.00
Экспрессия (8 полей)
Tissue expression
—
0.00
In vitro
—
0.00
In vivo
BDNF gene therapy in multiple mouse models of Alzheimer's disease
0.90
In silico
—
0.00
Genetic association
—
0.00
Ex vivo
—
0.00
Animal model
mouse models of Alzheimer's disease (including APP/PS1dE9, 5XFAD, Aβ and tau-driven models)
0.90
Diet/model
—
0.00
Клиника (11 полей)
Drug
BDNF gene therapy
0.90
Indication
Alzheimer's disease
1.00
Patient subgroups
—
0.00
Safety concerns
—
0.00
Off-target
—
0.00
Trial stage
Preclinical
0.90
Pharma competitors
—
0.00
AE severity
—
0.00
MOA weight loss
—
0.00
Endpoints
—
0.00
Approved
False
1.00